Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed metastatic renal cell carcinoma with measurable disease.~2. Adequate tumor tissue properly stored and available to produce lysate for a minimum of three vaccine preparations.~3. Patients must be at least 4 weeks from their last therapy (tyrosine kinase inhibitors, immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosureas) and recovered from all ill effects.~4. Have measurable disease.~5. Patients must be at least 4 weeks from major surgery, 1 week from minor surgery, and recovered from all ill effects.~6. Karnofsky Performance Status ≥80%.~7. Adequate end organ function:~8. Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study.~9. Appropriate contraception in both genders.~10. The patient must be competent and have signed informed consent.~11. Patients may have received one prior therapy with targeted therapies (e.g. sorafenib and sunitinib).~Exclusion Criteria:~1. Patients who have previously received bevacizumab or IL-2 are not eligible.~2. Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence or breast CIS.~3. In patients with a prior history of invasive malignancy, less than five years in complete remission.~4. Positive serology for HIV, hepatitis B or hepatitis C which should be confirmed with antigenemia.~5. Significant co-morbid illness such as uncontrolled diabetes or active infection that would preclude treatment on this regimen.~6. Use of corticosteroids or other immunosuppression (if patient had been taking steroids, at least 2 weeks must have passed since the last dose). Inhaled steroids \> 1000mcg beclomethasone per day or its equivalent.~7. History of inflammatory bowel disease or other serious autoimmune disease. (Not including thyroiditis and rheumatoid arthritis).~8. Patients with organ allografts.~9. Uncontrolled hypertension (BP \>150/100 mmHg).~10. Proteinuria dipstick \> 3+ or \> 2gm/24 hours, or a urine protein:creatinine ratio \> 1.0 at screening.~11. Major surgery, open biopsy, significant traumatic injury within 28 days of starting treatment or anticipation of need for major surgical procedure during the course of the study.~12. Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to starting treatment. Central venous catheter placements are permitted.~13. History of abdominal fistula, gastrointestinal perforation, or intrabdominal abscess within 6 months prior to starting treatment.~14. Serious, non-healing wound, ulcer, or bone fracture.~15. History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy.~16. History of deep venous thrombosis, or other thrombotic event within the past six months or clinically significant peripheral vascular disease.~17. Inability to comply with study and/or follow-up procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bevacizumab,IL-2, IFN, DC vaccine (Type: EXPERIMENTAL): Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)

Based on this trial design, predict the completion outcome and termination type (if applicable).